Clinical trials: Cancer Patients With Cancer Pain
Pain, Advanced Cancer
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer.
- Trial name
- NCT01337089
- Testing
- Nabiximols
- Where
- 128 sites in United States, Australia and 16 more
- Volunteers
- 660 people
- Sponsor
- Jazz Pharmaceuticals
Uterine Fibroids (MeSH Heading: Leiomyoma)
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain
- Trial name
- NCT05445167
- Testing
- KLH-2109
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Opioid-Induced Constipation
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
The purpose of this study is to compare the effect of NKTR-118 with placebo in the treatment of opioid-induced constipation (OIC) in patients with cancer-related pain, including those patients that have inadequate response to…
- Trial name
- NCT01384292
- Testing
- NKTR-118
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Breast Cancer, Multiple Myeloma
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion.
- Conditions
- Breast Cancer, Multiple Myeloma, Prostate Cancer
- Trial name
- NCT00029224
- Testing
- zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Novartis
Constipation
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
- Trial name
- NCT00365820
- Testing
- Tegaserod
- Where
- 59 sites in United States
- Volunteers
- 670 people
- Sponsor
- Novartis
Opioid-induced Constipation
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation (OIC) in patients with non-cancer pain.
- Trial name
- NCT00399659
- Testing
- Tegaserod
- Where
- 57 sites in United States
- Volunteers
- 360 people
- Sponsor
- Novartis
Pain
Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid
The primary purpose of this study is to evaluate the usefulness of hydromorphone to treat cancer pain in patients who have not been treated with a strong opioid.
- Trial name
- NCT01532895
- Testing
- Hydromorphone HCI OROS
- Where
- 11 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- Janssen Korea, Ltd., Korea
Neuroma
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma.
- Trial name
- NCT00130962
- Testing
- ALGRX 4975
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AlgoRx Pharmaceuticals
Pain, Bone Neoplasm
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00099203
- Testing
- ibandronate [Bondronat], zoledronic acid
- Where
- 72 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second…
- Trial name
- NCT01083615
- Testing
- custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Achieve Life Sciences
Chronic Pain, Neuropathic Pain
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.
- Conditions
- Chronic Pain, Neuropathic Pain, Cancer
- Trial name
- NCT00911261
- Testing
- Oxymorphone Extended Release
- Volunteers
- 223 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pain; Cancer
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics
The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl D-Trans (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01060124
- Testing
- Fentanyl D-trans
- Volunteers
- 103 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cancer
PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain
The aim of the study is to evaluate the efficacy of TARGIN administration as an analgesic to Korean patients treated with opioid analgesics for moderate-to-severe cancer pain under conditions of daily practice.
- Trial name
- PROBE (NCT01719757)
- Testing
- Oxycodone/Naloxone
- Where
- South Korea
- Volunteers
- 359 people
- Sponsor
- Mundipharma Korea Ltd
Cancer Pain
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.
- Trial name
- NCT00766831
- Testing
- Hydromorphone
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
Opioid Induced Constipation
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical…
- Trial name
- NACASY (NCT03638440)
- Testing
- Naloxegol
- Where
- 10 sites in Denmark, Finland and 8 more
- Volunteers
- 183 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus…
- Trial name
- NCT03294577
- Testing
- Pegfilgrastim, Plinabulin, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 20 sites in China, Ukraine
- Volunteers
- 221 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Pain, Intractable
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
The purpose of this study is to verify the effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, or 50 mcg/hr in Japanese patients with cancer pain who have…
- Trial name
- NCT00216658
- Testing
- fentanyl
- Volunteers
- 87 people
- Sponsor
- Janssen Pharmaceutical K.K.
Opioid-Induced Constipation
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been…
- Trial name
- NCT02270983
- Testing
- Linaclotide 145 micrograms, Linaclotide 290 micrograms
- Where
- 77 sites in United States
- Volunteers
- 254 people
- Sponsor
- Forest Laboratories
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis